NCT07470996

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 58 (estimated)
• Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the alternative salvage regimens. It aims to evaluate the efficacy and safety of Allo-HSCT and alternative salvage regimens in the treatment of peripheral T-cell lymphoma that has achieved no response (NR) after first-line therapy. During the screening/baseline period, informed consent will be obtained, and inclusion/exclusion criteria will be verified. Group assignment (Allo-HSCT vs. alternative salvage regimens) will be determined taking into account the availability of a matched donor and the patient's preference. The study plans to enroll 29 patients in each group. Data on demographics and medical history will be collected, and assessments including vital signs, physical examination, PET-CT, bone marrow aspiration smear, flow cytometry, and bone marrow pathology will be performed.

Conditions

• Peripheral T Cell Lymphoma

Interventions

Type	Name	Description
PROCEDURE	Allogenic stem cell transplant (ASCT)	ASCT involves the infusion of stem cells collected from a donor (genetically similar, but not identical).
PROCEDURE	Salvage Therapy	This term encompasses a range of potential alternative regimens instead of allogeneic hematopoietic stem cell transplantation

Timeline

• Start date: 2025-10-01
• Primary completion: 2029-05-30
• Completion: 2029-09-30
• First posted: 2026-03-13
• Last updated: 2026-03-13

Locations

1 site across 1 country: China